Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 24 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,230.00 and $565.00 suggesting an average analyst share price target price of $1,045.03. (at the time of writing). Given that the stocks previous close was at $716.26 this is indicating there is a potential upside of 45.9%. It’s also worth noting that there is a 50 day moving average of $772.37 and the 200 day moving average is $968.53. The market cap for the company is 80.25B. Currently the stock stands at: $730.30 USD
The potential market cap would be $117,089,889,895 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.05, revenue per share of $128.69 and a 7.41% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
